Summit Therapeutics Reveals Positive Phase II Trial Data for Ivonescimab

Summit Therapeutics (NASDAQ:SMMT) presented promising results from its international Phase II AK112-206 trial, showing a strong objective response rate of 70.8% in patients with first-line metastatic colorectal cancer treated with ivonescimab combined with standard chemotherapy.

By Muhammad Ali Khalid Fri, June 5, 2026 at 7:36 PM GMT+3 2 min read · Yahoo Finance · June 5, 2026, 16:36 UTC

Summit Therapeutics Reveals Positive Phase II Trial Data for Ivonescimab

Tickers: $SMMT

Topics: biopharma colorectal cancer ivonescimab oncology

Read the full article at Yahoo Finance

More World news

Oman Investment Authority Signs Multi-Billion Dollar Investment Package with Chinese Partners PR Newswire · November 12, 2026, 15:52 UTC
Nvidia Shares Drop 35% Following Resignation of CEO Jensen Huang Motley Fool · November 12, 2026, 15:49 UTC
Pomerantz Law Firm Investigates Potential Securities Fraud at ClearPoint Neuro (CLPT) PR Newswire · November 12, 2026, 15:50 UTC
Nvidia CEO Jensen Huang Resigns Amid Board Investigation The Verge · November 12, 2026, 15:48 UTC
GFL Environmental Shares Decline Following Preferred Share Conversion and Block Trade Seeking Alpha · November 12, 2026, 15:48 UTC
Medical Facilities Corp. Announces CAD 0.09 Per Share Quarterly Dividend Seeking Alpha · November 12, 2026, 15:45 UTC
Micron Shares Decline Following Resignation of Nvidia CEO Jensen Huang Motley Fool · November 12, 2026, 15:44 UTC
Wirex Launches Navoka AI Agent with Dedicated Bank Account and Card PR Newswire · November 12, 2026, 15:44 UTC
Mobility Global Shares Rise 12% Following Q3 Earnings Beat and Improved EBITDA Outlook Seeking Alpha · November 12, 2026, 15:44 UTC
Lucid Diagnostics Reports Q3 2026 Results Amid Transition to Medicare Reimbursement Motley Fool · November 12, 2026, 15:39 UTC